Margarita Chavez, J.D.
Margarita is Managing Director at Abbvie Ventures. Margarita has lead investments in over a dozen biotech companies in the US and Europe and is responsible for AbbVie’s investments in Morphic Therapeutics, Palleon Pharmaceuticals, eFFECTOR Therapeutics, CARISMA Therapeutics, Jnana Therapeutics and Paragen Bio. Margarita brings over 20 years of dealmaking experience, with over a decade in biotech M&A, licensing, and venture.
Margarita was previously a Director with Abbott’s Global Pharmaceutical Licensing & Acquisitions. Among others, Margarita was involved in the in-licensing of Elagolix, the acquisition of Immuven, and the acquisition of the Lupron franchise. Before joining Abbott, Margarita practiced as a corporate and securities lawyer in Silicon Valley with the firm of Brobeck Phleger & Harrison, advising in equity financings, M&A and IPOs.
Margarita currently serves as a Board Member of the New England Venture Capital Association and the MidAmerica Healthcare Investors Network and on the Advisory Board of the Santa Clara University School of Law.